p53 Expression in Biopsies From Children With Langerhans Cell Histiocytosis
- 1 December 2002
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of Pediatric Hematology/Oncology
- Vol. 24 (9) , 733-736
- https://doi.org/10.1097/00043426-200212000-00010
Abstract
Langerhans cell histiocytosis (LCH) is a rare pediatric and adult disease causing skin rashes, osteolytic bone lesions, tumorous growth in various organs, and in some patients, organ dysfunction. The cause of the disease is obscure, and it is not yet understood why some patients develop single-system lesions only without relapse, whereas others develop fatal multiorgan disease. The expression of p53 tumor suppressor gene product detected immunohistochemically can be used as a guideline to alterations in DNA repair control and apoptosis. The authors have chosen to analyze p53 expression in biopsies from children with LCH and correlate it with clinical manifestation and outcome in a broad range of organs. The study was performed on 50 specimens from 32 children (19 boys and 13 girls), median age 3 1/4 years, range 5 months to 12 1/3 years with a definite diagnosis of LCH based on CD1a positivity. The slides were stained with p53 antibody and semiquantitatively evaluated using a grading system from 1 to 5 as an estimate for 0% to 20%, 20% to 40%, 40% to 60%, 60% to 80%, and 80% to 100%p53-positive for pathologic Langerhans cells (pLC), respectively. The p53 protein was expressed in various degrees in pLC in all lesions. The degree of p53 expression could not be correlated to either clinical manifestation or outcome. An increased expression of p53 in pLC indicates an altered DNA repair control with or without abnormal control of apoptosis.Keywords
This publication has 15 references indexed in Scilit:
- CURRENT THERAPY FOR LANGERHANS CELL HISTIOCYTOSISHematology/Oncology Clinics of North America, 1998
- p53 Expression in Langerhans Cell HistiocytosisJournal of Pediatric Hematology/Oncology, 1998
- DNA Polymorphisms and Mutations of the Tumor Necrosis Factor-α(TNF-α) Promoter in Langerhans Cell Histiocytosis (LCH)Journal of Interferon & Cytokine Research, 1997
- Contemporary classification of histiocytic disordersMedical and Pediatric Oncology, 1997
- Langerhans cell histiocytosis (histiocytosis X)Published by Oxford University Press (OUP) ,1997
- Cell Cycle Control and CancerScience, 1994
- Langerhans'-Cell Histiocytosis (Histiocytosis X) -- A Clonal Proliferative DiseaseNew England Journal of Medicine, 1994
- Efficacy of ifosfamide, dacarbazine, doxorubicin and cisplatin in human sarcoma xenograftsBritish Journal of Cancer, 1994
- Clonal proliferation of Langerhans cells in Langerhans cell histiocytosisPublished by Elsevier ,1994
- Treatment strategy for disseminated langerhans cell histiocytosisMedical and Pediatric Oncology, 1994